Smart Sourcing: Critical Questions Pharma Brands Must Ask Potential CDMOs
Selecting a Contract Development and Manufacturing Organization (CDMO) is a high-stakes decision for any pharmaceutical brand. A wrong medkinglifescience.com choice can trigger regulatory delays, supply chain failures, or catastrophic batch recalls. To secure a resilient partnership, pharma brands must look past marketing brochures and ask deep, operational questions.
1. Regulatory Compliance and Audit Viability
Regulatory compliance is the foundation of pharmaceutical manufacturing. Brands must verify that a facility can withstand intense global scrutiny.
- What specific international regulatory certifications does this facility hold? Ensure active clearances from relevant bodies like the FDA, EMA, or local authorities.
- Can we review your complete history of regulatory audits and Form 483 observations? Examine past deficiencies and the corrective and preventive actions (CAPA) implemented to resolve them.
- What are our rights regarding facility access and physical audits? A trustworthy partner must allow both scheduled and unannounced site visits, alongside full access to batch records.
2. Specialized Technical Capability
Equipment alone does not guarantee a successful product. The facility must possess specific expertise tailored to your drug molecule.
- How many successful technology transfers have you completed for our exact dosage form? Confirm extensive experience with your specific delivery mechanism, whether it involves sterile injectables, topicals, or complex oral solids.
- What specific protocols do you use to prevent cross-contamination for highly potent APIs? Evaluate their use of dedicated HVAC systems, isolated containment areas, and validated equipment-cleaning methodologies.
3. Supply Chain Integrity and Operational Scale
A robust drug profile matters little if the manufacturer cannot guarantee consistent material sourcing or scale production efficiently.
- Where are your raw materials sourced, and how do you verify vendor quality? Ensure all active ingredients and excipients come from pre-qualified suppliers backed by validated Certificates of Analysis (COA).
- What is your Minimum Order Quantity (MOQ) per batch, and how much open capacity do you possess? Confirm that their operational baseline aligns with your current commercial forecast, while leaving room for sudden market scaling.
4. Commercial Clarity and Risk Management
Operational transparency safeguards your budget and intellectual property from unexpected legal or financial disputes.
Can you provide a granular breakdown of all manufacturing, testing, and packaging costs? Avoid hidden fees by insisting on transparent line-item pricing.
Who legally owns the intellectual property for formulation optimizations made during tech transfer? Protect your brand by ensuring all product refinements remain your exclusive property.
What is your standard protocol for investigating out-of-specification (OOS) results? Establish clear communication timelines and dispute resolution workflows for handling manufacturing deviations.